Tango Therapeutics, Inc. · NASDAQ:TNGX
Tango Therapeutics — JP Morgan Healthcare Conference 2026
24 slides from Tango Therapeutics's conference presentation, Jan 8, 2026
Slide 1: The next wave of targeted therapies in oncology
The next wave of targeted therapies in oncology JP Morgan Healthcare Conference January 12, 2026
Slide 2: Disclaimer and safe harbor statement
Disclaimer and safe harbor statement Certain statements in this presentation may be considered forward-looking statements. Forward-looking statements generally relate to future events, Tango’s future financial and operating performance, goals, expectations, beliefs, development plans, as well as dev
Slide 3: Malte Peters, MD President and CEO to lead our next phase of growth
Malte Peters, MD President and CEO to lead our next phase of growth Accomplished leader with deep clinical development expertise • Member of Tango Board of Directors since 2018 • Previous roles - Chief Research and Development Officer, MorphoSys AG and member of the Management Board - Global Head of
Slide 4: MTAP deletion is one of the most common genetic changes in cancer
MTAP deletion is one of the most common genetic changes in cancer MTAP del % Number of cases NSCLC 15% Large unmet need Pancreatic* 35% GBM/glioma 45% • MTAP deletion confers sensitivity to PRMT5 inhibitors Head and Neck 16% • Large opportunity for development Bladder 25% in pancreatic and lung canc
Slide 5: A pipeline targeting multiple high value indications with MTAP deletion
A pipeline targeting multiple high value indications with MTAP deletion PATIENT TARGET MOLECULE INDICATIONS CLINICAL TRIALS STATUS SELECTION PRE-CLINICAL PHASE 1/2 PHASE 3 MTAP-del Pancreatic, lung, Dose expansion ongoing cancers other non-CNS cancer Vopimetostat (TNG462) MTAP-del/ PRMT5 RAS-mut Pan
Slide 6: Key 2025 achievements
Key 2025 achievements Advancing multiple clinical programs Creating value for patients Vopimetostat Pipeline Financial/Corporate • Clinical data supporting • TNG456 (brain penetrant • $225M equity raise vopimetostat as a potentially PRMT5 inhibitor) in phase 1/2 • $343M* cash balance as of best-in-c
Slide 7: Competitive advantage drives 2026 strategic execution
Competitive advantage drives 2026 strategic execution Complete Expand Launch pivotal study vopimetostat/RASi vopimetostat data in Evaluate TNG456 in 2L pancreatic study to support 1L lung/other cancers efficacy in cancer pivotal study in to support additional glioblastoma pancreatic cancer pivotal s
Slide 8: Pipeline poised to deliver meaningful clinical benefit in multiple common cancers with MTAP deletion
Pipeline poised to deliver meaningful clinical benefit in multiple common cancers with MTAP deletion Potential best-in-class oral PRMT5 inhibitors Vopimetostat TNG456 TNG961 • Key indications* • Brain penetrant PRMT5 inhibitor • HBS1L degrader synthetic lethal being developed for glioblastoma with F
Slide 9: Vopimetostat demonstrates clear monotherapy activity across histologies
Vopimetostat demonstrates clear monotherapy activity across histologies Active doses >6 mo follow-up Key points n=94 • ORR 27% in 16 different histologies • mPFS 6.4 months • DCR 78% • 37/94 patients ongoing • Median follow-up 9.4 months • Good tolerability with no discontinuations for drug related
Slide 10: Vopimetostat mPFS in 2L pancreatic cancer more than twice historical SOC trials
Vopimetostat mPFS in 2L pancreatic cancer more than twice historical SOC trials Key points • ORR in 2L PDAC 25% (2/8 evaluable pts) • Vopimetostat 2L mPFS 7.2 mo • SOC chemotherapy mPFS 2-3.5 mo • Vopimetostat pivotal study control arm may have lower mPFS than historical controls, increasing probabi
Slide 11: Vopimetostat pivotal trial in 2L pancreatic cancer
Vopimetostat pivotal trial in 2L pancreatic cancer Pivotal study start planned 2026 vopimetostat 250mg QD n~150 2L MTAP-del pancreatic cancer SOC chemotherapy n~150 Planning for 2L registration • FDA supportive of study design • Rapid enrollment of ~300 patients anticipated given high unmet medical
Slide 12: Vopimetostat + zoldonrasib has striking efficacy in preclinical models
Vopimetostat + zoldonrasib has striking efficacy in preclinical models Vopimetostat + zoldonrasib Key points KP4 • Pancreatic cancer is a RAS-addicted MTAP-null, KRASG12D PDAC CDX cancer • Almost all MTAP-del pancreatic cancers have a RAS mutation • ~40% MTAP del pancreatic ca is RAS G12D mut • Simi
Slide 13: Encouraging early activity in ongoing vopimetostat + RAS(ON) inhibitor clinical study
Encouraging early activity in ongoing vopimetostat + RAS(ON) inhibitor clinical study Study update DOSE ESCALATION • Ongoing robust enrollment • 30 patients dosed vopimetostat—14 pts with vopimetostat/daraxonrasib Any RAS mut + daraxonrasib—16 pts with vopimetostat/zoldonrasib 2L+ MTAP-del/RAS mut p
Slide 14: Vopimetostat + RASi strategy for 1L pancreatic cancer
Vopimetostat + RASi strategy for 1L pancreatic cancer RAS inhibitors likely to replace chemotherapy as SOC in 1L pancreatic cancer • More than 90% of pancreatic cancers are RAS-driven1 • Almost all MTAP-del pancreatic cancers have a RAS mutation • ~18k pts with MTAP-del and RAS-mut pancreatic cancer
Slide 15: Vopimetostat 49% ORR in histology selective cohort
Vopimetostat 49% ORR in histology selective cohort Tumor evaluable pts at active doses with >6 months follow-up Key points (n=37) • ORR 49% • mPFS 9.1 months • DCR 89% • 21/37 patients ongoing • Median follow-up 9.5 months • Excludes sarcoma, pancreatic and lung cancer • Ongoing Cholangiocarcinoma M
Slide 16: Vopimetostat 9.1 mo mPFS more than twice historical SOC trials in multiple indications
Vopimetostat 9.1 mo mPFS more than twice historical SOC trials in multiple indications mPFS (95% CI) 9.1 months (6.5 – 12.0) Durable activity in multiple late line, difficult to treat cancers provides: • Further evidence of robust single agent activity • Additional optionality for development in lar
Slide 17: TNG456 PRMT5 inhibition being developed for MTAP-deleted glioblastoma
TNG456 PRMT5 inhibition being developed for MTAP-deleted glioblastoma
Slide 18: TNG456 is a next-generation CNS-penetrant PRMT5 inhibitor
TNG456 is a next-generation CNS-penetrant PRMT5 inhibitor Brain penetrance provides potential to address high unmet need in glioblastoma • Enhanced potency and MTAP selectivity • Predicted brain exposure well above efficacy threshold • In development for MTAP-del glioblastoma (7,000 patients/yr US)1
Slide 19: TNG456 phase 1/2 clinical study in MTAP-del solid tumors
TNG456 phase 1/2 clinical study in MTAP-del solid tumors Summary • Dose escalation ongoing DOSE ESCALATION DOSE EXPANSION • Abemaciclib combination to start with evidence of single agent Glioblastoma activity in GBM TNG456 • FDA Fast Track designation • FDA Orphan Drug Designation for glioblastoma
Slide 20: TNG961 HBS1L degrader for FOCAD-del/MTAP-del cancers
TNG961 HBS1L degrader for FOCAD-del/MTAP-del cancers
Slide 21: FOCAD deletion and HBS1L are a synthetic lethal pair
FOCAD deletion and HBS1L are a synthetic lethal pair FOCAD deletion confers HBS1L FOCAD deletion occurs in one third of MTAP-del cancers dependency for RNA stability HBS1L RPS6 ACER2 SLC24A2 MLLT3 FOCAD TNG961 (HBS1L degrader) HACD4 IFNB1 KLHL9 MTAP Vopimetostat CDKN2A Release PELO CDKN2B ribosome D
Slide 22: TNG961 drives tumor regression in FOCAD-del/MTAP-del preclinical models
TNG961 drives tumor regression in FOCAD-del/MTAP-del preclinical models Strong xenograft activity across lineages TNG961 • Potent and selective HBS1L molecular NCI-H838 MIAPACA2 glue degrader NSCLC PDAC • IC50 110 nM 2500 ) 1500 3 3 ) • 100X selectivity for FOCAD del vs WT m m 2000 m ( ( m e e 1000
Slide 23: Multiple projected key milestones and strong balance sheet
Multiple projected key milestones and strong balance sheet Clinical milestones Cash balance Vopimetostat lung ca data 2026 • $343M cash, cash equivalents and marketable Vopimetostat + daraxonrasib/zoldonrasib data securities as of December 31, 2025* 2026 • Cash runway into 2028 2L PDAC pivotal study
Slide 24: Tango Therapeutics
TANGO therapeutics
Tango Therapeutics — JP Morgan Healthcare Conference 2026 on 6ix